Purpose: Most patients with pancreatic ductal adenocarcinoma (PDAC) present with surgically unresectable cancer. As a result, endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA) is the most common biospecimen source available for diagnosis in treatment-naïve patients. Unfortunately, these limited samples are often not considered adequate for genomic analysis, precluding the opportunity for enrollment on precision medicine trials. Experimental Design: Applying an epithelial cell adhesion molecule (EpCAM)-enrichment strategy, we show the feasibility of using real-world EUS-FNA for in-depth, molecular-barcoded, whole-exome sequencing (WES) and somatic copy-number alteration (SCNA) analysis in 23 patients with PDAC. Results: Potentially actionable mutations were identified in >20% of patients. Further, an increased mutational burden and higher aneuploidy in WES data were associated with an adverse prognosis. To identify predictive biomarkers for first-line chemotherapy, we developed an SCNA-based complexity score that was associated with response to platinum-based regimens in this cohort. Conclusions: Collectively, these results emphasize the feasibility of real-world cytology samples for in-depth genomic characterization of PDAC and show the prognostic potential of SCNA for PDAC diagnosis.
|Number of pages||12|
|Journal||Clinical Cancer Research|
|State||Published - Feb 15 2021|
Bibliographical noteFunding Information:
We thank A.J. Aguirre, B.M. Wolpin, and the Hale Family Research Center at Dana-Farber Cancer Institute for providing an independent dataset used for replication of our results. Most of all we thank the patients and their families. A. Maitra is supported by the MD Anderson Pancreatic Cancer Moon Shot Program, the Khalifa Bin Zayed Al-Nahyan Foundation, and the NIH (U01CA196403, U01CA200468, and P50CA221707). A. Semaan is supported by the German Research Foundation (SE-2616/2–1). V. Bernard is supported by the NIH (U54CA096300, U54CA096297, and T32CA217789). J.J. Lee is supported by the NIH (T32CA009599).
A. Semaan reports grants from DFG during the conduct of the study. A. Maitra reports other from Cosmos Wisdom Biotech, Thrive Earlier Detection, and JNJ outside the submitted work. Y.A. Jakubek reports other from Invitae outside the submitted work. No disclosures were reported by the other authors.
© 2020 American Association for Cancer Research.
ASJC Scopus subject areas
- Medicine (all)